Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Operating Leases (2020 - 2025)

Historic Operating Leases for Pharma (IGC) over the last 6 years, with Q3 2025 value amounting to $5000.0.

  • Pharma's Operating Leases fell 8571.43% to $5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5000.0, marking a year-over-year decrease of 8571.43%. This contributed to the annual value of $10000.0 for FY2025, which is 9519.23% down from last year.
  • Per Pharma's latest filing, its Operating Leases stood at $5000.0 for Q3 2025, which was down 8571.43% from $7000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Operating Leases registered a high of $433000.0 during Q2 2021, and its lowest value of $5000.0 during Q3 2025.
  • For the 5-year period, Pharma's Operating Leases averaged around $205631.6, with its median value being $208000.0 (2024).
  • Its Operating Leases has fluctuated over the past 5 years, first dropped by 29.33% in 2023, then plummeted by 9519.23% in 2025.
  • Quarter analysis of 5 years shows Pharma's Operating Leases stood at $374000.0 in 2021, then plummeted by 35.56% to $241000.0 in 2022, then plummeted by 52.28% to $115000.0 in 2023, then plummeted by 89.57% to $12000.0 in 2024, then tumbled by 58.33% to $5000.0 in 2025.
  • Its Operating Leases was $5000.0 in Q3 2025, compared to $7000.0 in Q2 2025 and $10000.0 in Q1 2025.